Argenta Discovery 2009 Limited argenta@glpg.com www.argentadiscovery.com Tel: 01279 645645 A Galapagos Company, 8-9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR UK
A
Argenta is an integrated drug discovery contract research organisation based in Harlow, UK. We are part of the Galapagos group of companies, Europe’s largest drug discovery contract research organisation. Argenta is a trusted strategic partner with over 10 years experience in small molecule drug discovery and offers an integrated approach to complete drug discovery programmes as well as hit identification, hit to lead, and lead optimisation projects. Argenta has discovered an industry-leading number of development candidates for its clients. As well as complete projects, Argenta offers individual services on a fee-for-service basis, these include; biomarker identification, ADME, solid-state chemistry, process/scale-up chemistry and candidate de-risking services. Argenta is a successful and growing organisation that provides a high-quality, high-value service, and one able to contribute significantly to the generation of intellectual property. Ours and our clients’ success is a consequence of a focus on drug discovery expertise, achieved through our recruitment of exceptional scientists. Indeed Argenta scientists boast an average of over 16 year’s relevant drug discovery expertise.
B C D E F G
Asterand Zuleika Roberts zuleika.roberts@asterand.com www.asterand.com Tel: 01763 211600 2 Orchard Road, Roystonm, Hertfordshire SG8 5HD
H
Asterand is the leading global supplier of high quality, well characterized human tissue and human tissuebased research services to support drug discovery & development. We provide human based solutions to pharmaceutical and biotechnology companies to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with an increased likelihood of clinical success. Asterand has a significant and well established human tissue heritage, having been formed through the combination of three leading human tissue focussed organisations. Asterand offers unparalleled access to human tissues for research through its worldwide network of collaborative donor institutions. Asterand’s Services division offers exemplary scientific expertise in collaborative human tissue research. Our PhaseZERO® platform delivers human tissue-based data supporting target & biomarker validation and compound function & safety. Our BioMAP® platform, comprising a comprehensive panel of automated, human primary cell based disease systems, enables rapid input on mechanism of action, efficacy and side effect profiles of drug candidates, providing actionable data to guide lead selection and optimisation.
I J K L M
Astex Pharmaceuticals Inc
N
Jeremy Carmichael, Director of Business Development
O
info@astx.com www.astx.com Tel: 01223 226200 2 Orchard Road, Royston, Hertfordshire SG8 5HD
Astex Pharmaceuticals, Inc. is an international, NASDAQ-listed (ASTX) pharmaceutical company dedicated to the discovery and development of novel therapeutics with a focus on oncology. The Company’s proprietary pipeline of drugs is de-risked as a prelude to partnerships with leading pharmaceutical companies. Astex Pharmaceuticals was formed out of a merger between SuperGen and Astex Therapeutics with locations in Dublin, CA and Cambridge, UK. Astex Pharmaceuticals receives significant royalties on global sales of Dacogen® (decitabine) for Injection, a marketed drug developed by the company. In 2011, royalty revenue is forecasted to exceed $61million. Eisai and Janssen, the global marketers of Dacogen, have filed for approval of a new indication in both the US and EU. Astex Pharmaceuticals has a broad portfolio with four clinical programs that are expected to provide phase II proofof-concept data in 2012. Two of the programs, AT13387, an HSP90 inhibitor, and SGI110, a second generation hypomethylating agent, will be expanded in 2012 to test clinically additional indications. Astex has partnered development programs and ongoing collaborations with pharmaceutical companies including J&J, GSK, AZ and Novartis that could generate more than a billion dollars in milestone revenue as products and projects progress. Astex is a recognized world leader in fragment-based drug discovery and uses its proprietary technologies to generate new drug candidates across multiple therapeutic indications. The fragment-based approach to drug discovery has been shown to be successful at identifying small molecules with optimal drug-like properties against difficult targets. For more information about Astex Pharmaceuticals: http://www.astx.com.
P Q R S T
Beckman Coulter Genomics Liz Bland EBland@beckman.com www.beckmangenomics.com Tel: 01279 873837 Hope End, Takeley, Essex M22 6TA
U
Beckman Coulter Genomics is a leading provider of genomic services, serving life-science researchers and pharmaceutical industries throughout the world. By providing technical expertise, combined with personalized service, Beckman Coulter Genomics delivers the highest quality data, robust analyses and innovative thinking. Beckman Coulter Genomics has expertise and experience on a wide range of genomic technology platforms and is dedicated to delivering the highest quality results across the extensive range of genomic services provided. Beckman Coulter Genomics services include: Sequencing Beckman Coulter Genomics offers a comprehensive range of sequencing services for individual samples, high-throughput projects and custom strategies using both Sanger and next generation technologies, enabling high quality data generation for diverse applications. Services include whole genome and transcriptome analysis, targeted resequencing and metagenomics. Genotyping Beckman Coulter Genomics use multiple platforms in support of a comprehensive genotyping offering including clinical genotyping, genome-wide association, chromosome copy number, linkage analyses and population genetic studies. Gene Expression Profiling For profiling across multiple platforms, Beckman Coulter Genomics have a suite of gene expression tools. Our experienced team of molecular and computational biologists enables you to fully incorporate transcript profiling into target prioritization and validation, lead screening, toxicity profiling, mechanism of action and pre-clinical/clinical studies. Biologics Testing Beckman Coulter Genomics offers a group of services aimed to evaluate the identity, stability, purity, and safety of biological products. These services are compliant with GLP/cGMP regulations and include microbial detection/differentiation, cell bank characterization, residual DNA analysis and biodistribution studies.
V W X Y Z
www.onenucleus.com
ONENUC(2012).indd 71
71
1/2/12 16:39:05